News blog

Entelos Inc

  • BY: Andrew Hore |
  • POSTED: 21/11/2008 |

Delays in drug development programmes have hit fourth quarter revenues at Entelos Inc.

California-based Entelos develops predictive biosimulation models, which can be used instead of animals to test drugs. The disappointing trading means that the company’s 2008 revenues will be below expectations. A 2008 loss of £450,000 was originally forecast.

Cash flow is improving and the rate of cash burn will be lower in the second half. The full year figures will be released in March 2009.

Shares in the company fell 2p to 3p each, which values Entelos at £1.81m.

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds